News

CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2017-09-15
  • Views:0

(Summary description)China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech Biomedical Technologies (Suzhou) Co., Ltd.'s clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

CGeneTech's Class I innovative drug Centagliptin phosphate enters Phase I clinic

(Summary description)China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech Biomedical Technologies (Suzhou) Co., Ltd.'s clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2017-09-15
  • Views:0

  China is a major diabetic country with over 100 million diabetic patients, ranking first in the world. CGeneTech(Suzhou,China)Co.,Ltd's clinical trial application for a Class I innovative drug, Centagliptin phosphate, for the treatment of type 2 diabetes was approved by the State Food and Drug Administration in May 2017. At present, Centec has entered into an agreement with institutions including Jiangsu Provincial People's Hospital to conduct the Phase I clinical trial of Centagliptin phosphate. Centagliptin phosphate belongs to the dipeptidyl peptidase (DPP)-4 inhibitor class, which has the greatest advantage of not causing hypoglycaemia and weight gain, and is cardiovascular protective; at the same time, Chinese patients with type 2 diabetes benefit more from DPP-4 inhibitors because they have more damaged pancreatic beta cells than those in Europe and the US, and one of the features of DPP-4 inhibitors is that they can improve beta cell damage. This has led to the increasing acceptance of DPP-4 inhibitors by doctors in China.

 Cetagliptin phosphate is a new diabetes drug developed by the National 12th Five-Year Plan and Jiangsu Province's Science and Technology Support Program. The pre-clinical studies of Cetagliptin phosphate have shown that it is 3-10 times more effective than the world's best drug, Selegiline phosphate (Genovate), and more than 5 times safer than Selegiline phosphate, which is a clear advantage. The successful launch of Cetagliptin phosphate will bring a more affordable, safe and effective drug option to hundreds of millions of Chinese type 2 diabetes patients and will further improve the treatment of type 2 diabetes in China. Centurion will always take independent innovation as the driving force for its development, continue to undertake the mission of developing new drugs for major diseases in China, work closely with academic forces at home and abroad, and actively explore the development of China's pharmaceutical technology industrialisation for the benefit of Chinese patients.

Brainstorming

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.
2024-05-28
Shengshi

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.
2024-05-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO